Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Greetings, and welcome to the Achieve Life Sciences Third Quarter ...
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...
Watch out, Gilead and Novartis: there's a new CAR-T in town. Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy ...
From STAT’s Elaine Chen: Earlier this month, the FDA updated the labels of GLP-1 drugs to warn of the risk of patients ...
TipRanks on MSN13h
Syncona’s Autolus Gains FDA Approval for Leukemia TherapySyncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA approval for AUCATZYL®, a ...
Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...
“Without FDA approval, consumers must rely on their own research to evaluate and identify trustworthy brands,” notes Will ...
The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the ...
The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback